Previsioni

Il prezzo obiettivo medio degli analisti è +80,14€ (+49,54%). La mediana è +77,26€ (+44,17%).

Acquista	19
Mantieni	14
Vendi	0

Notizie Vai al feed delle notizie

Strong quarterly results drive Ionis Pharmaceuticals stock higher premarket

Ionis Pharmaceuticals reported a loss per share of $0.69 and revenue of $268 million in the second quarter, with both metrics comfortably beating consensus expectations. The results point to faster‑than‑expected sales for Tryngolza (Olezarsen), despite a substantial price cut ahead of broader approval. After the stock plunged following the failure of the Phase‑3 CARDIO‑TTRansform study, the premarket recovery now reflects the solid commercial numbers and positive analyst commentary, with an average 12‑month price target of about $92.95. » Altro su de.investing.com
Ionis treats first patient in phase‑1/2 study of Dravet pill ION337

Ionis has treated the first participant in the open-label phase‑1/2 ASCEND study of ION337 for the treatment of Dravet syndrome. ION337 is intended to increase production of the NaV1.1 protein and uses the N‑methylacetamide (NMA) modification; the FDA has granted the drug Fast Track designation. The study includes a one-month single ascending dose phase followed by 24 months of multiple ascending dosing and a seven-month safety follow-up in children aged 2–12 years. Ionis most recently reported revenue of $1.06 billion (+48% year/year) but remains unprofitable with a loss of $2.02 per share; market capitalization is $9.63 billion and analysts' price targets range between $68 and $125. » Altro su de.investing.com
Study failure for eplontersen weighs on Ionis Pharmaceuticals stock

The phase‑3 CARDIO‑TTRansform study with eplontersen missed the primary endpoint of the composite of cardiovascular mortality and recurrent events through week 140, after which Ionis Pharmaceuticals shares fell about 20.7% in premarket trading. CARDIO‑TTRansform, with 1,432 patients, was the largest study to date in ATTR‑CM and was viewed as a key growth driver for Ionis through 2026. A pre‑specified subgroup analysis showed a nominally significant hazard ratio for eplontersen as monotherapy, but this was not enough to offset the failure of the overall study. The result strengthens competitors such as Alnylam in the ATTR‑CM market and forces investors to reassess the near‑term commercial prospects for eplontersen. » Altro su de.investing.com

Dividendi storici Dividendi

Tutte le metriche sui dividendi Tutte le metriche

Nel 2000, Ionis Pharmaceut ha già distribuito 0,67€ di dividendi. L'ultimo pagamento è avvenuto a maggio 2000.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Ionis Pharmaceut ha registrato ricavi pari a 234.78m€ e un utile netto di −100.45m€

(EUR)	giu 2026	YoY
Ricavi	+234.78m	38,78%
Utile lordo	+232.38m	38,85%
Utile netto	−100.45m	195,83%
EBITDA	−92.29m	172,41%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+8.94b€
Numero di azioni	166.18m
Massimo/minimo a 52 settimane	+74,46€ - +36,16€
Dividendi	No
Beta	0,4
Rapporto P/E	−18,11
Rapporto PEG	+0,22
Rapporto P/B	+23,57
Rapporto P/S	+11,92

Profilo aziendale

Ionis Pharmaceuticals, Inc. erforscht und entwickelt in den Vereinigten Staaten RNA-gezielte Therapeutika. Das Unternehmen bietet SPINRAZA für spinale Muskelatrophie (SMA) bei pädiatrischen und erwachsenen Patienten, TEGSEDI, eine Injektion zur Behandlung der Polyneuropathie der hereditären Transthyretin-vermittelten Amyloidose bei Erwachsenen, und WAYLIVRA, eine Behandlung für das familiäre Chylomikronämie-Syndrom und die familiäre partielle Lipodystrophie. Darüber hinaus entwickelt das Unternehmen Medikamente für verschiedene Indikationen, die sich in Phase-3-Studien befinden, darunter Eplontersen als monatliche subkutane Injektion zur Selbstverabreichung zur Behandlung aller Arten von TTR-Amyloidose; Olezarsen für Patienten mit schwerer Hypertriglyceridämie (SHTG); Donidalorsen für Patienten mit hereditärem Angioödem; ION363 für Patienten mit amyotropher Lateralsklerose; Pelacarsen für Patienten mit etablierten Herz-Kreislauf-Erkrankungen und erhöhtem Lipoprotein(a); und Tofersen zur Hemmung der Produktion von Superoxid-Dismutase 1. Darüber hinaus entwickelt das Unternehmen Medikamente für Stoffwechselkrankheiten, Infektionskrankheiten, Nierenkrankheiten, Augenkrankheiten und Krebs. Es unterhält eine strategische Zusammenarbeit mit Biogen Inc. sowie Kooperations- und Lizenzvereinbarungen mit AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc. und Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. wurde 1989 gegründet und hat seinen Sitz in Carlsbad, Kalifornien.

Nome	Ionis Pharmaceut
CEO	Brett Monia
Sede centrale	Carlsbad, ca Stati Uniti
Sito web	ionispharma.com
Settore	Sanità
Industria	Prodotti farmaceutici
Quotazione in borsa	17/05/1991
Dipendenti	1.480